Welcome to our dedicated page for Vaxart news (Ticker: VXRT), a resource for investors and traders seeking the latest updates and insights on Vaxart stock.
Vaxart, Inc. develops oral recombinant pill vaccines based on a proprietary delivery platform. The clinical-stage biotechnology company’s programs include vaccine candidates for coronavirus, norovirus and influenza, as well as a therapeutic human papillomavirus vaccine as its first immune-oncology indication. Its pill-based vaccines are designed for oral administration, storage and shipping without refrigeration, and avoidance of needle-stick risk.
Vaxart news centers on clinical data and scientific publications, business updates, financial results, financing arrangements, collaborations, intellectual property around adenovirus and TLR3 agonist oral vaccination technology, and governance changes as the company advances its oral vaccine pipeline.
Vaxart (OTCQX: VXRT) filed a preliminary proxy statement for its July 16, 2026 annual meeting and issued a letter urging support for its current Board. The company highlights full enrollment of its BARDA-supported Phase 2b COVID-19 oral vaccine trial, progress in norovirus and influenza programs, and actions taken to extend cash runway into Q2 2027, including a Dynavax strategic partnership, cost reductions, and a $25 million share purchase agreement.
Vaxart (OTCQX: VXRT) provided a business update and first-quarter 2026 results on May 7, 2026. Key items: topline data from a 400-person sentinel cohort in its Phase 2b COVID-19 trial is expected in Q2 2026; cash, cash equivalents, and investments were $61.0 million as of March 31, 2026 with runway into Q2 2027; revenue was $39.2 million for Q1 2026 and net income was $5.2 million. Other items: cumulative BARDA payments of $218.9 million, a share purchase agreement up to $25 million, norovirus program updates, and a May 8, 2026 stockholder fireside chat.
Vaxart (OTCQX: VXRT) will host a virtual stockholder fireside chat on May 8, 2026 at 4:30 p.m. ET. Management will answer shareholder questions. The company will report Q1 2026 financial results after market close on May 7, 2026. A live webcast and replay will be available at the company website.
Vaxart (OTCQX: VXRT) appointed James Breitmeyer, M.D., Ph.D., to its Board of Directors on April 23, 2026. Dr. Breitmeyer brings more than 35 years of biopharmaceutical experience and leadership in clinical development, including programs that led to eight FDA product approvals.
His background includes recent executive roles at Altay Therapeutics (joined Feb 2026) and prior leadership at Oncternal Therapeutics and Bavarian Nordic, plus senior roles at Eli Lilly and Cadence Pharmaceuticals, adding regulatory and vaccine development expertise to the Board.
Vaxart (OTCQX: VXRT) entered a share purchase agreement with Lincoln Park Capital providing the company the right to sell up to $25 million of common stock over a 24-month period. Vaxart retains sole discretion on timing and amounts; Lincoln Park must buy at prevailing market prices.
The SPA contains no warrants or participation rights, Lincoln Park agreed not to short or hedge, and Vaxart issued shares as consideration. Sales require a registration statement to be declared effective by the SEC before any shares are sold under the facility.
Vaxart (OTCQX: VXRT) reported full-year 2025 results and a business update on March 12, 2026. Key points: $237.3M revenue, $16.3M net income, $63.8M cash and investments and runway into Q2 2027. The company highlighted a Dynavax collaboration and upcoming Phase 2b COVID-19 data.
Clinical: topline 400-person sentinel cohort data expected early Q2 2026; full ~5,000-participant readout expected Q4 2026. January 2026 norovirus data showed maternal breast milk IgA transfer to infants.
Vaxart (NASDAQ: VXRT) will host two webcasts: a Full Year 2025 Business Update and Financial Results call on March 12, 2026 at 4:30 p.m. ET, and a Stockholder Fireside Chat on March 13, 2026 at 4:30 p.m. ET.
Both events will be webcast live on the company website, include senior management participation, accept investor questions in advance via ir@vaxart.com, and will be available on replay after the events.
Vaxart (OTCQX: VXRT) announced that management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Wednesday, February 25, 2026 at 4:00 PM ET.
The virtual presentation will be webcast and available on the company investor relations website for 30 days following the event; management will also hold one-on-one meetings.
Vaxart (OTCQX: VXRT) published Phase 1, double-blind, placebo-controlled data showing a single-dose oral bivalent norovirus vaccine was safe and well-tolerated in lactating women and induced norovirus-specific antibodies in serum and breast milk.
The study reported norovirus-specific IgA in breastfed infants' stool that correlated with breast milk IgA, suggesting passive transfer of mucosal immunity to infants. Results were published in npj Vaccines on Jan 15, 2026.
Vaxart (OTCQX: VXRT) will present at the virtual Global BioInnovation Forum on Tuesday, January 13, 2026. Senior leaders speaking are Steven Lo (CEO), Sean Tucker, Ph.D. (Founder & Chief Scientific Officer) and James F. Cummings, M.D. (Chief Medical Officer).
The presentation is scheduled for 11:30am PT / 2:30pm ET. A live webcast will be available via the company's investor relations website and will remain accessible for 30 days after the event.